Sarah R Leist

List of Publications by Citations

54 papers	**7,159** citations	**27** h-index	**62** g-index
62 ext. papers	**9,809** ext. citations	**17.2** avg, IF	**6** L-index

#	Paper	IF	Citations
54	Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. *Nature Communications*, **2020**, 11, 222	17.4	1059
53	Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. *Science Translational Medicine*, **2017**, 9,	17.5	983
52	SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. *Cell*, **2020**, 182, 429-446.e14	56.2	710
51	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. *Nature*, **2020**, 586, 567-571	50.4	594
50	An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. *Science Translational Medicine*, **2020**, 12,	17.5	534
49	SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. *Science*, **2020**, 370, 1464-1468	33.3	517
48	Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis. *MBio*, **2018**, 9,	7.8	431
47	A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. *Nature*, **2020**, 586, 560-566	50.4	299
46	Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. *Cell Reports*, **2020**, 32, 107940	10.6	260
45	A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice. *Cell*, **2020**, 183, 1070-1085.e12	56.2	224
44	Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. *Cell*, **2020**, 183, 1367-1382.e17	56.2	217
43	Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. *Journal of Experimental Medicine*, **2021**, 218,	16.6	171
42	SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. *Nature*, **2021**, 591, 451-457	50.4	131
41	Middle East Respiratory Syndrome Coronavirus Nonstructural Protein 16 Is Necessary for Interferon Resistance and Viral Pathogenesis. *MSphere*, **2017**, 2,	5	71
40	High Potency of a Bivalent Human V Domain in SARS-CoV-2 Animal Models. *Cell*, **2020**, 183, 429-441.e16	56.2	67
39	SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness **2020**,		62
38	A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures **2020**,		58

#	Reference	IF	Citations
37	Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 29832-29838	11.5	57
36	Swine acute diarrhea syndrome coronavirus replication in primary human cells reveals potential susceptibility to infection. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 26915-26925	11.5	49
35	Combination Attenuation Offers Strategy for Live Attenuated Coronavirus Vaccines. *Journal of Virology*, **2018**, 92,	6.6	48
34	Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. *Science*, **2021**, 373, 991-998	33.3	48
33	SARS-CoV-2 D614G Variant Exhibits Enhanced Replication and Earlier Transmission **2020**,		41
32	Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. *EBioMedicine*, **2020**, 62, 103132	8.8	39
31	A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. *Vaccines*, **2020**, 8,	5.3	38
30	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. *Cell*, **2021**, 184, 5432-5447.e16	56.2	34
29	Influenza H3N2 infection of the collaborative cross founder strains reveals highly divergent host responses and identifies a unique phenotype in CAST/EiJ mice. *BMC Genomics*, **2016**, 17, 143	4.5	33
28	In vivo knockdown of Piccolino disrupts presynaptic ribbon morphology in mouse photoreceptor synapses. *Frontiers in Cellular Neuroscience*, **2014**, 8, 259	6.1	31
27	Cell and animal models of SARS-CoV-2 pathogenesis and immunity. *DMM Disease Models and Mechanisms*, **2020**, 13,	4.1	26
26	Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice. *Cell Reports*, **2021**, 36, 109450	10.6	23
25	Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022. *JCI Insight*, **2021**, 6,	9.9	22
24	Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection **2020**,		21
23	Tmprss2 knock-out mice are resistant to H10 influenza A virus pathogenesis. *Journal of General Virology*, **2019**, 100, 1073-1078	4.9	19
22	Rapid selection of a human monoclonal antibody that potently neutralizes SARS-CoV-2 in two animal models **2020**,		19
21	Stabilized coronavirus spike stem elicits a broadly protective antibody. *Cell Reports*, **2021**, 37, 109929	10.6	18
20	COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. *Immunity*, **2021**, 54, 1869-1882.e6	32.3	16

19 | Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice **2020**, | | 15

18 | Giving the Genes a Shuffle: Using Natural Variation to Understand Host Genetic Contributions to Viral Infections. *Trends in Genetics*, **2018**, 34, 777-789 | 8.5 | 14

17 | Modeling pathogenesis of emergent and pre-emergent human coronaviruses in mice. *Mammalian Genome*, **2018**, 29, 367-383 | 3.2 | 14

16 | A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine **2020**, | | 13

15 | Of mice and men: the host response to influenza virus infection. *Mammalian Genome*, **2018**, 29, 446-470 | 3.2 | 12

14 | Remdesivir Potently Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. *SSRN Electronic Journal*, | 1 | 11

13 | Chimeric spike mRNA vaccines protect against Sarbecoviru challenge in mice **2021**, | | 11

12 | Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection. *PLoS Pathogens*, **2021**, 17, e1009897 | 7.6 | 11

11 | Genetically Engineering a Susceptible Mouse Model for MERS-CoV-Induced Acute Respiratory Distress Syndrome. *Methods in Molecular Biology*, **2020**, 2099, 137-159 | 1.4 | 11

10 | Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2 **2020**, | | 10

9 | Increasing the translation of mouse models of MERS coronavirus pathogenesis through kinetic hematological analysis. *PLoS ONE*, **2019**, 14, e0220126 | 3.7 | 9

8 | Complex Genetic Architecture Underlies Regulation of Influenza-A-Virus-Specific Antibody Responses in the Collaborative Cross. *Cell Reports*, **2020**, 31, 107587 | 10.6 | 9

7 | Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate **2020**, | | 8

6 | Baseline T cell immune phenotypes predict virologic and disease control upon SARS-CoV infection in Collaborative Cross mice. *PLoS Pathogens*, **2021**, 17, e1009287 | 7.6 | 8

5 | H2 influenza A virus is not pathogenic in Tmprss2 knock-out mice. *Virology Journal*, **2020**, 17, 56 | 6.1 | 6

4 | Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice **2021**, | | 5

3 | Lst1 deficiency has a minor impact on course and outcome of the host response to influenza A H1N1 infections in mice. *Virology Journal*, **2016**, 13, 17 | 6.1 | 4

2 | Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2. *Journal of Virology*, **2021**, 95, e0097421 | 6.6 | 3

1   Ex vivo and in vivo suppression of SARS-CoV-2 with combinatorial AAV-RNAi expression vectors..
     Molecular Therapy, **2022**,   11.7   1

5